Last update Jan. 11, 2020
Very Low Risk
We do not have alternatives for Buserelin Acetate since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Buserelin Acetate is also known as Buserelin.
Buserelin Acetate in other languages or writings:
Buserelin Acetate belongs to this group or family:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 0 | % |
Molecular weight | 1.239 | daltons |
Protein Binding | 15 | % |
Tmax | 1 | hours |
T½ | 1.3 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by AELAMA of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Decapéptido de síntesis, similar a la gonadorelina, análogo de la hormona liberadora de la hormona luteinizante natural (LHRH).
Indicado en tratamientos de fecundación in vitro antes de la estimulación con gonadotropinas exógenas para estimulación ovárica.
Administración subcutánea diaria durante 15 a 21 días.
Se utiliza también en carcinoma de próstata y endometriosis.
La buserelina, administrada por inhalación intranasal, se excreta en leche materna en cantidad ínfima o indetectable y no produce alteraciones hormonales en lactantes amamantados por madres que la tomaban (Dewart 1987) ni alteraciones en la lactancia (Fraser 1989).
Su peso molecular elevado explicaría este ínfimo paso a leche materna.
Por su naturaleza proteica es inactivado en el tracto gastrointestinal (Van Leusden 1994, Fraser 1993), no absorbiéndose, (biodisponibilidad oral prácticamente nula), lo que dificulta o impide el paso a plasma del lactante a partir de la leche materna ingerida, salvo en prematuros y periodo neonatal inmediato, en los que puede haber mayor permeabilidad intestinal.
En mujeres tratadas con análogos de la gonadorelina y gonadotrofinas se ha observado aumento de prolactina (Cavagna 2005, Kamel 1994, Meldrum 1992), aunque el hallazgo no es constante (Chantilis 1995).
See below the information of these related products: